GlassScriptPhysician profile
Sukriti Kamboj
NPI 1134475650
$3,752.99
in general payments reported to CMS, 2019-2025
45 companies · $1,140 in 2025
The $1,140 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $821 · 2020: $452 · 2022: $106 · 2023: $576 · 2024: $659 · 2025: $1,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,340 · Education: $34.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,340.08 |
| Education | $34.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $415.49 | 2019-2025 | |
| Celgene Corporation | $381.35 | 2019-2025 | Opdivo, Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $294.11 | 2019-2025 | Keytruda, Lynparza |
| Amgen INC. | $194.24 | 2019-2020 | |
| Janssen Biotech, INC. | $193.66 | 2022-2025 | Erleada, Tecvayli, Talvey |
| Incyte Corporation | $193.54 | 2019-2023 | Jakafi |
| Novartis Pharmaceuticals Corporation | $191.29 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $187.36 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Astellas Pharma US INC | $145.38 | 2019-2025 | Padcev, Xtandi, Vyloy |
| Takeda Pharmaceuticals U.S.A., INC. | $136.28 | 2019 | |
| Exelixis INC. | $115.83 | 2023-2025 | Cabometyx |
| Daiichi Sankyo INC. | $98.51 | 2020-2024 | Enhertu |
| Glaxosmithkline, LLC. | $98.45 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Eisai INC. | $92.90 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $87.56 | 2019-2025 | Ultomiris |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sukriti Kamboj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.